EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.
You may also be interested in...
Novartis To Launch Exforge In September 2007
Company cannot market the hypertension combination drug until expiration of exclusivity for Pfizer’s Norvasc.
Novartis To Launch Exforge In September 2007
Company cannot market the hypertension combination drug until expiration of exclusivity for Pfizer’s Norvasc.
Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
Combination of olmesartan and amlodipine can be used alone or in conjunction with other antihypertensives, firm says.